BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27138458)

  • 1. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
    Joseph RW; Cappel M; Tzou K; Bagaria S; Gilstrap C; Swaika A; Jambusaria-Pahlajani A
    Melanoma Res; 2016 Aug; 26(4):409-12. PubMed ID: 27138458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
    Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
    Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
    Miller AK; Dusing R; Meggison A; Aires D
    J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
    Florin V; Desmedt E; Vercambre-Darras S; Mortier L
    Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
    Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
    J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
    Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
    Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local cryosurgery and imiquimod: A successful combination for the treatment of locoregional cutaneous metastasis of melanoma: A case series.
    Rivas-Tolosa N; Ortiz-Brugués A; Toledo-Pastrana T; Baradad M; Traves V; Soriano V; Sanmartín V; Requena C; Martí R; Nagore E
    J Dermatol; 2016 May; 43(5):553-6. PubMed ID: 26660713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of locally metastatic melanoma: a novel approach.
    Shistik G; Prakash AV; Fenske NA; Glass LF
    J Drugs Dermatol; 2007 Aug; 6(8):830-2. PubMed ID: 17763615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
    Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P
    Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
    Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
    Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Hell J Nucl Med; 2017; 20(3):251-253. PubMed ID: 29177265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod in the treatment of metastatic melanoma to skin.
    Wolf IH; Smolle J; Binder B; Cerroni L; Richtig E; Kerl H
    Arch Dermatol; 2003 Mar; 139(3):273-6. PubMed ID: 12622616
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
    Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
    Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
    Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
    Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
    [No Abstract]   [Full Text] [Related]  

  • 16. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
    Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
    Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Topical treatment of melanoma skin metastases with imiquimod].
    Sigüenza M; Pizarro A; Mayor M; Vidaurrázaga C; Miralles L; González-Beato M; Casado M
    Actas Dermosifiliogr; 2005 Mar; 96(2):111-5. PubMed ID: 16476347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature.
    Ellis LZ; Cohen JL; High W; Stewart L
    Dermatol Surg; 2012 Jun; 38(6):937-46. PubMed ID: 22338583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
    Ray CM; Kluk M; Grin CM; Grant-Kels JM
    Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.